Literature DB >> 27404860

Duchenne muscular dystrophy drugs at the crossroads, as newer agents advance.

Cormac Sheridan.   

Abstract

Entities:  

Year:  2016        PMID： 27404860     DOI： 10.1038/nbt0716-675

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

1.  EMA reconsiders 'read-through' drug against Duchenne muscular dystrophy following appeal.

Authors:  Asher Mullard
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 54.908

2.  Very mild muscular dystrophy associated with the deletion of 46% of dystrophin.

Authors:  S B England; L V Nicholson; M A Johnson; S M Forrest; D R Love; E E Zubrzycka-Gaarn; D E Bulman; J B Harris; K E Davies
Journal:  Nature       Date:  1990-01-11       Impact factor: 49.962

Review 3.  The emperor's new dystrophin: finding sense in the noise.

Authors:  S D Wilton; R N Veedu; S Fletcher
Journal:  Trends Mol Med       Date:  2015-06-04       Impact factor: 11.951

Review 4.  Molecular mechanisms of muscular dystrophies: old and new players.

Authors:  Kay E Davies; Kristen J Nowak
Journal:  Nat Rev Mol Cell Biol       Date:  2006-09-13       Impact factor: 94.444

Review 5.  A chemical view of oligonucleotides for exon skipping and related drug applications.

Authors:  Peter Järver; Liz O'Donovan; Michael J Gait
Journal:  Nucleic Acid Ther       Date:  2013-10-30       Impact factor: 5.486
  5 in total
  3 in total

1.  Drugmakers accused of exploiting orphan drug incentives, fueling price problem.

Authors:  Brady Huggett
Journal:  Nat Biotechnol       Date:  2017-04-11       Impact factor: 54.908

2.  Fresh from the biotech pipeline-2016.

Authors:  Chris Morrison
Journal:  Nat Biotechnol       Date:  2017-01-30       Impact factor: 54.908

3.  Conditional Approval Pathways: The "Special" Case of Global Regenerative Medicine Regulation.

Authors:  James A Smith; David A Brindley
Journal:  Rejuvenation Res       Date:  2017-02       Impact factor: 4.663
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.